Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 4, 2018, Pages E733-E742

  Mazor, Ronit ^a   King, Emily M ^a   Onda, Masanori ^a   Cuburu, Nicolas ^a   Addissie, Selamawit ^a,c   Crown, Devorah ^a   Liu, Xiu Fen ^a   Kishimoto, Takashi Kei ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Selecta Biosciences   (United States)

^c NantKwest Inc   (United States)

Author keywords

Antidrug antibodies; Cancer; Mesothelin; Nanoparticle; Rapamycin

Indexed keywords

DRUG ANTIBODY; IMMUNOTOXIN; LMB 100; NANOPARTICLE; RAPAMYCIN; SYNTHETIC VACCINE NANOPARTICLE; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOSUPPRESSIVE AGENT; MESOTHELIN; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MESOTHELIOMA CELL LINE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; LEUKEMIA; TIME FACTOR;

ANIMALS; ANTIBODIES, NEUTRALIZING; GPI-LINKED PROTEINS; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; LEUKEMIA; NANOPARTICLES; SIROLIMUS; TIME FACTORS;

EID: 85040864373     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1717063115     Document Type: Article

References (48)

1. Maus MV, et al. (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1:26–31.
2. Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1:241–254.
3. Chung CH, et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109–1117.
4. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15:5274–5279.
5. Sun JY, Chatterjee S, Wong KK, Jr (2002) Immunogenic issues concerning recombinant adeno-associated virus vectors for gene therapy. Curr Gene Ther 2:485–500.
6. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ (2010) Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 1:314–322.
7. Hassan R, et al. (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120:3311–3319.
8. Kreitman RJ (2009) Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 15:2652–2664.
9. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565.
10. Kreitman RJ, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822–1828.
11. Kreitman RJ, et al. (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622–1636.
12. Mazor R, Onda M, Pastan I (2016) Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev 270:152–164.
13. Hassan R, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149.
14. Hassan R, et al. (2013) Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5: 208ra147.
15. Liu W, et al. (2012) Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 109:11782–11787.
16. Alewine C, et al. (2014) Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther 13: 2653–2661.
17. Stallone G, et al. (2016) mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med 14:152.
18. Mossoba ME, et al. (2011) Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res 17: 3697–3705.
19. Kishimoto TK, et al. (2016) Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol 11:890–899.
20. Zhang AH, Rossi RJ, Yoon J, Wang H, Scott DW (2016) Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation. Cell Immunol 301:74–81.
21. Maldonado RA, et al. (2015) Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci USA 112:E156–E165.
22. Getts DR, Shea LD, Miller SD, King NJ (2015) Harnessing nanoparticles for immune modulation. Trends Immunol 36:419–427.
23. Onda M, et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105: 11311–11316.
24. + phagocytes. Eur J Immunol 40:780–786.
25. Onda M, et al. (2014) Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol 193:48–55.
26. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791–5802.
27. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40:2969–2975.
28. Mezzapelle R, et al. (2016) Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep 6:22850.
29. Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I (2004) Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 10:16–18.
30. + T regulatory cells. J Immunol 176:3301–3305.
31. + T regulatory cells.” J Immunol 177:2036, author reply 2037–2038.
32. + T regulatory cells.” J Immunol 177:2036–2037, author reply 2037–2038.
33. Peffault de Latour R, et al. (2006) Ontogeny, function, and peripheral homeostasis of regulatory T cells in the absence of interleukin-7. Blood 108:2300–2306.
34. Kreitman RJ, et al. (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729.
35. Velazquez VM, et al. (2017) Effective depletion of pre-existing anti-AAV antibodies requires broad immune targeting. Mol Ther Methods Clin Dev 4:159–168.
36. Law BK (2005) Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 56:47–60.
37. O’Donnell JS, Massi D, Teng MWL, Mandala M (May 2, 2017) PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol, 10.1016/j.semcancer.2017.04.015.
38. Antignani A, et al. (2016) Chemical screens identify drugs that enhance or mitigate cellular responses to antibody-toxin fusion proteins. PLoS One 11:e0161415.
39. Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem 21:797–802.
40. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA (2012) Size matters: Gold nanoparticles in targeted cancer drug delivery. Ther Deliv 3:457–478.
41. Leshem Y, et al. (2017) Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity. Cancer Immunol Res 5:685–694.
42. Selby MJ, et al. (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1: 32–42.
43. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205:825–839.
44. Guo Z, et al. (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 9:e89350.
45. Bauss F, et al. (2016) Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Mol Oncol 10: 1317–1329.
46. Mazor R, et al. (2017) Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. Cell Mol Immunol 14:432–442.
47. Hollevoet K, et al. (2014) In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 13:2040–2049.
48. + T cell responses. J Clin Invest 122:4606–4620.